NCT01205815 Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment
| NCT ID | NCT01205815 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vanderbilt-Ingram Cancer Center |
| Condition | Melanoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2010-06-03 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2010-06-03 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research is to identify biological characteristics occurring in the initiation and progression of melanoma.
Eligibility Criteria
Inclusion criteria * Pathologically-proven diagnosis of melanoma. * Patient must have a test or procedure that has the potential to provide left-over tissue that can be banked for future research purposes OR the patient has already had a diagnostic or therapeutic procedure but who has not yet been approached to participate is also eligible. Exclusion criteria * Any patient with significant contraindications to venipuncture (e.g., severe anemia) will be excluded from blood collection procedures. However, if the patient provides consent and a paraffin-embedded block or 10-15 unstained slides of their tissue diagnosis, they will not be excluded from this protocol. * Any patient unable or unwilling to provide consent.
Contact & Investigator
Vanderbilt-Ingram Service for Timely Access
📞 800-811-8480
Douglas Johnson, M.D.
PRINCIPAL INVESTIGATOR
Vanderbilt-Ingram Cancer Center
Frequently Asked Questions
Who can join the NCT01205815 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Melanoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01205815 currently recruiting?
Yes, NCT01205815 is actively recruiting participants. Visit ClinicalTrials.gov or contact Vanderbilt-Ingram Cancer Center to inquire about joining.
Where is the NCT01205815 trial being conducted?
This trial is being conducted at Nashville, United States.
Who is sponsoring the NCT01205815 clinical trial?
NCT01205815 is sponsored by Vanderbilt-Ingram Cancer Center. The principal investigator is Douglas Johnson, M.D. at Vanderbilt-Ingram Cancer Center. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.